ARGX vs GILD: stock comparison and AI forecast
Argenx Se (ARGX) and Gilead Sciences, Inc. (GILD) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ARGX Argenx Se
- Price
- $901.12 +13.4% · 6M
- Market Cap
- $55.76B
- P/E Ratio
- 23.6x
- Size
- large-cap
- AI Forecast
GILD Gilead Sciences, Inc.
- Price
- $167.47 +25.5% · 6M
- Market Cap
- $207.72B
- P/E Ratio
- –
- Size
- mega-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- GILD is 3.7 times larger than ARGX by market capitalization ($207.72B against $55.76B).
- Over the last six months GILD returned +25.5% and ARGX +13.4%.
- GILD carries 2.95 times debt per unit of equity, against 0.19 times for ARGX.
- GILD yields 1.97% in dividends; ARGX pays none.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ARGX | GILD |
|---|---|---|
| Market Cap | $55.76B | $207.72B |
| P/E Ratio | 23.64x | – |
| P/B Ratio | – | 15.93x |
| Dividend Yield | – | 1.97% |
| EPS | $38.12 | $-3.15 |
| Book Value/Share | – | $10.51 |
| Revenue/Share | – | $24.98 |
| FCF/Share | $13.34 | $11.11 |
Profitability & Margins
| Metric | ARGX | GILD |
|---|---|---|
| ROE | 34.2% | -29.6% |
| ROA | 28.9% | -7.5% |
| ROIC | 16.8% | -6.0% |
| Gross Margin | – | 79.9% |
| Operating Margin | – | -7.6% |
| Net Margin | – | -12.5% |
| EBT Margin | – | -8.2% |
| Tax Rate | -42.2% | -52.5% |
Financial Health
| Metric | ARGX | GILD |
|---|---|---|
| Current Ratio | 5.23x | 1.38x |
| Quick Ratio | 4.87x | 1.22x |
| D/E Ratio | 0.19x | 2.95x |
| Financial Leverage | 1.19x | 3.94x |
| Interest Coverage | – | 1.9x |
| Working Capital | $5.58B | $4.55B |
Cash Flow
| Metric | ARGX | GILD |
|---|---|---|
| Operating Cash Flow | $840M | $14.48B |
| Free Cash Flow | $826M | $13.78B |
| Capital Spending | -$14M | -$699M |
| OCF Growth YoY | – | 49.8% |
| FCF Growth YoY | 0.0% | 50.4% |
| FCF/Sales | – | 44.5% |
| CapEx/Sales | – | 2.3% |
Operational Efficiency
| Metric | ARGX | GILD |
|---|---|---|
| Asset Turnover | – | 0.60x |
| Receivables Turnover | – | 6.2x |
| Inventory Turnover | 2.0x | 3.3x |
| Fixed Assets Turnover | – | 5.2x |
| Days Sales Outstanding | – | 59 days |
| Days Inventory | 179 days | 111 days |
| Payables Period | 479 days | 55 days |
| Cash Conversion Cycle | – | 115 days |
Income Statement
| Metric | ARGX | GILD |
|---|---|---|
| Total Revenue | – | $30.99B |
| Operating Income | $1.23B | -$2.36B |
| Net Income | $2.51B | -$3.86B |
| R&D Expense | $3.43B | $6.33B |
| SG&A Expense | $3.52B | $6.81B |
| Cost of Goods Sold | $965M | $6.22B |
Dividend & Shareholder Information
| Metric | ARGX | GILD |
|---|---|---|
| Dividends Per Share | – | $3.31 |
| Shares Outstanding | 62M | 1240M |
| Net Income Growth | – | -147.6% |
| EPS Growth | – | -148.8% |
ARGX vs GILD: stock comparison and AI forecast
Which is bigger, ARGX or GILD?
GILD is 3.7 times larger than ARGX by market capitalization ($207.72B against $55.76B).
Which stock performed better over the last six months, ARGX or GILD?
Over the last six months GILD returned +25.5% and ARGX +13.4%.
Which one does Intratio's AI model rank higher, ARGX or GILD?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.